Cartesian Therapeutics (RNAC) Profit After Tax (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Profit After Tax of -$39.2 million for Q1 2026, down 121.24% year-over-year from $184.5 million in Q1 2025, and up 57.69% quarter-over-quarter from -$92.6 million in Q4 2025.
Cartesian Therapeutics (RNAC) Profit After Tax (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Profit After Tax for 12 consecutive years, with -$39.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 121.24% year-over-year to -$39.2 million; the TTM figure through Mar 2026 stood at -$151.8 million (down 296.17% YoY), while the FY2025 annual figure was -$130.3 million, down 68.3% from the prior year.
- Profit After Tax rose to -$39.2 million in Q1 2026 per RNAC's latest filing, from -$92.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at $28.8 million in Q1 2022 and bottomed at -$177.7 million in Q4 2023.
- Historically, Profit After Tax has averaged -$25.4 million across 5 years, with a median of -$11.4 million in 2023.
- Annual changes were most pronounced in 2023 — Profit After Tax slumped 3110.64% — and 2024, when it surged 221.51%.
- Cartesian Therapeutics' Profit After Tax stood at $5.9 million in 2022, then plunged by 3110.64% to -$177.7 million in 2023, then surged by 94.23% to -$10.2 million in 2024, then slumped by 803.78% to -$92.6 million in 2025, then jumped by 57.69% to -$39.2 million in 2026.
- Business Quant data shows RNAC's Profit After Tax at -$39.2 million in Q1 2026, -$92.6 million in Q4 2025, and -$35.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.77 Mn |
| Mar 31, 2026 | -39.18 Mn |
| Dec 31, 2025 | -92.61 Mn |
| Sep 30, 2025 | -35.90 Mn |
| Jun 30, 2025 | 15.89 Mn |
| Mar 31, 2025 | -17.71 Mn |
| Dec 31, 2024 | -10.25 Mn |
| Sep 30, 2024 | -24.20 Mn |
| Jun 30, 2024 | 13.84 Mn |
| Mar 31, 2024 | -56.82 Mn |
| Dec 31, 2023 | -177.66 Mn |
| Sep 30, 2023 | -9.02 Mn |
| Jun 30, 2023 | -11.39 Mn |
| Mar 31, 2023 | -21.66 Mn |
| Dec 31, 2022 | 5.90 Mn |
| Sep 30, 2022 | -7.94 Mn |
| Jun 30, 2022 | 8.60 Mn |
| Mar 31, 2022 | 28.78 Mn |
| Dec 31, 2021 | 12.24 Mn |
| Sep 30, 2021 | -17.90 Mn |